Abstract
Introduction: Colorectal cancer (CRC) is a common type of cancer with a relatively poor survival rate. The survival rate of patients could be improved if CRC is detected early. Biomarkers associated with early stages of tumour development might provide useful tools for the early diagnosis of colorectal cancer.
Area covered: Online searches using PubMed and Google Scholar were performed using keywords and with a focus on recent proteomic studies. The aim of this review is to highlight the need for biomarkers to improve the detection rate of early CRC and provide an overview of proteomic technologies used for biomarker discovery and validation. This review will also discuss recent proteomic studies which focus on identifying biomarkers associated with the early stages of CRC development.
Expert opinion: A large number of CRC biomarkers are increasingly being identified by proteomics using diverse approaches. However, the clinical relevance and introduction of these markers into clinical practice cannot be determined without a robust validation process. The size of validation cohorts remains a major limitation in many biomarker studies.
Area covered: Online searches using PubMed and Google Scholar were performed using keywords and with a focus on recent proteomic studies. The aim of this review is to highlight the need for biomarkers to improve the detection rate of early CRC and provide an overview of proteomic technologies used for biomarker discovery and validation. This review will also discuss recent proteomic studies which focus on identifying biomarkers associated with the early stages of CRC development.
Expert opinion: A large number of CRC biomarkers are increasingly being identified by proteomics using diverse approaches. However, the clinical relevance and introduction of these markers into clinical practice cannot be determined without a robust validation process. The size of validation cohorts remains a major limitation in many biomarker studies.
| Original language | English |
|---|---|
| Pages (from-to) | 55-63 |
| Number of pages | 9 |
| Journal | Expert Review of Proteomics |
| Volume | 15 |
| Issue number | 1 |
| Early online date | 6 Nov 2017 |
| DOIs | |
| Publication status | Published - 2018 |
Bibliographical note
Funding: This manuscript was not funded.Keywords
- Biomarker
- colorectal cancer
- diagnosis
- early detection
- proteomics
- screening
- FECAL IMMUNOCHEMICAL TEST
- URINARY PGE-M
- BIOMARKER DISCOVERY
- MASS-SPECTROMETRY
- CLINICAL IMPACT
- BLOOD-TEST
- MISS RATE
- ADENOMAS
- PROTEINS
- PROGRESSION
Access to Document
- Accepted Manuscript
This is an Accepted Manuscript of an article published by Taylor & Francis in Expert Review of Proteomics on 06 Nov 2017, available online: http://www.tandfonline.com/10.1080/14789450.2018.1396893